Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Nuvectis Pharma Stock Performance
NVCT stock traded down $0.37 during midday trading on Friday, reaching $9.25. The stock had a trading volume of 105,945 shares, compared to its average volume of 126,411. The firm has a fifty day simple moving average of $8.74 and a two-hundred day simple moving average of $7.17. The stock has a market cap of $216.38 million, a PE ratio of -7.97 and a beta of -0.11. Nuvectis Pharma has a 52-week low of $4.44 and a 52-week high of $11.80.
Insider Buying and Selling
In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri bought 240,000 shares of Nuvectis Pharma stock in a transaction dated Friday, February 7th. The stock was acquired at an average cost of $5.00 per share, with a total value of $1,200,000.00. Following the purchase, the insider now directly owns 2,884,121 shares in the company, valued at $14,420,605. This represents a 9.08 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 35.78% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several brokerages have commented on NVCT. Maxim Group began coverage on shares of Nuvectis Pharma in a research note on Wednesday, April 2nd. They set a "buy" rating and a $17.00 price objective for the company. Laidlaw initiated coverage on shares of Nuvectis Pharma in a report on Monday, March 17th. They issued a "buy" rating and a $19.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $15.00 price objective (up previously from $11.00) on shares of Nuvectis Pharma in a research note on Wednesday.
Check Out Our Latest Analysis on NVCT
Nuvectis Pharma Company Profile
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
See Also
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
